SCHEMBL414036

SCHEMBL414036

O=C(O)Cc1ccc2ncsc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.58
RAB9A P51151 6/20 0.58
KDM4E B2RXH2 4/20 0.58
TDP1 Q9NUW8 3/20 0.58
HKDC1 Q2TB90 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GAA P10253 2/20 0.46
ALDH1A1 P00352 2/20 0.46
FFAR1 O14842 1/20 0.45
GABRP O00591 2/20 0.45
GABRD O14764 2/20 0.45
GABRA1 P14867 2/20 0.45
GABRB1 P18505 2/20 0.45
GABRG2 P18507 2/20 0.45
GABRB3 P28472 2/20 0.45
GABRA5 P31644 2/20 0.45
GABRA3 P34903 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9326866 0.87 KDM4E (0.52) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL421391 0.85 NPC1 (0.53) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL27174606 0.85 RAB9A (0.53) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL418265 0.84 KDM4E (0.55) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL3590811 0.81 RAB9A (0.56) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL15286656 0.80 NPC1 (0.54) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL27493244 0.79 RAB9A (0.51) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL506620 0.79 NPC1 (0.51) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL31078903 0.78 NPC1 (0.53) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL20563305 0.77 NPC1 (0.51) NPC1RAB9AKDM4ETDP1HKDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119735869-A Low-zinc environment-friendly rubber composition and preparation method thereof 濮阳科茂威新材料股份有限公司 2025-04-01 CN claimed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
CN-119735869-A Low-zinc environment-friendly rubber composition and preparation method thereof 濮阳科茂威新材料股份有限公司 2025-04-01 CN disclosed
WO-2024233642-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed
EP-3519409-C0 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION GILEAD SCIENCES INC (US) 2024-09-18 EP disclosed
EP-3519409-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION GILEAD SCIENCES INC (US) 2024-09-18 EP disclosed
EP-3519409-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION GILEAD SCIENCES INC (US) 2024-09-18 EP disclosed
US-20230339890-A1 AMINO ALCOHOL COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-10-26 US disclosed
US-20230339890-A1 AMINO ALCOHOL COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-10-26 US disclosed
US-20230257353-A1 IONIZABLE LIPIDOIDS AND THEIR USES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-17 US disclosed
EP-0431943-B1 Spiro(pyran)piperidine derivatives MERCK & CO INC (US) 1998-07-15 EP disclosed
US-5633247-A ANTIARRTHYMIA AGENT MERCK & CO., INC. (US) 1997-05-27 US disclosed
EP-0646112-A4 TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS. ABBOTT LAB (US) 1997-04-02 EP disclosed
EP-0646112-A1 TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS ABBOTT LABORATORIES (US) 1995-04-05 EP disclosed
US-5288749-A Treating central nervous system or cardiovascular disorders ABBOTT LABORATORIES (US) 1994-02-22 US disclosed
WO-1993012754-A2 TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS ABBOTT LABORATORIES (US) 1993-07-08 WO disclosed
US-5206240-A Antiarrhythmia agents MERCK & CO., INC. (US) 1993-04-27 US disclosed
EP-0431943-A2 Nitrogen-containing spirocycles MERCK & CO. INC. (US) 1991-06-12 EP disclosed
EP-0153230-B1 PYRIMIDO(2,1-B)BENZOTHIAZOLE DERIVATIVES AND THEIR SALTS, PROCESS AND PREPARATION INTERMEDIATES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1989-07-19 EP disclosed
EP-0153230-A2 Pyrimido(2,1-b)benzothiazole derivatives and their salts, process and preparation intermediates, their use as medicaments and compositions containing them ROUSSEL-UCLAF (FR) 1985-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257353-A1 IONIZABLE LIPIDOIDS AND THEIR USES TTR, PYGL, FABP1 NPC1 29/4885RAB9A 3208/4885KDM4E 4697/4885
US-20230339890-A1 AMINO ALCOHOL COMPOUNDS AND USES THEREOF AADAT, SLC1A2, SLC1A1 NPC1 1685/4885RAB9A 3148/4885KDM4E 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.